Register Now

EC approves Sandoz's biosimilars for bone-related ailments

Wyost and Jubbonti are approved as biosimilars of reference medicines Xgeva and Prolia.

Evotec shuts down gene therapy business in light of Q1 2024 loss

Evotec will close an Austrian facility as it shuts down its gene therapy business Evotec GT, a move which will affect 40 employees.

Merck's MilliporeSigma agrees to acquire Mirus Bio for $600m

The deal bolsters capabilities in viral vector manufacturing for advanced cell and gene therapies.

NICE recommends Rhythm's Imcivree for rare genetic obesity disorder

Rhythm expects Imcivree will be available on the NHS in England and Wales within the next three months.

IR-MED's PressureSafe device cuts pressure injury incidence by half

The PressureSafe device reduced the incidence of pressure injuries by 50% by detecting these pressure injuries to the skin and underlying tissue early.

Coya Therapeutics concludes Phase II Alzheimer's therapy trial

Topline results from the trial are expected to be reported in the third quarter of 2024.

Adlai Nortye starts subject dosing in Phase II rectal cancer trial

The trial will enrol 140 subjects to assess efficacy of TNT with or without AN0025.

13th Annual Clinical Trials in Oncology East Coast 2024

The upcoming Clinical Trials In Oncology West Coast 2024 will bring together pharma and biotech experts to discuss clinical-stage cancer therapy development.